Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sti-001

STI-001 SIGNED

Turn Cancer Immunotherapy Effective in Most Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STI-001 project word cloud

Explore the words cloud of the STI-001 project. It provides you a very rough idea of what is the project "STI-001" about.

durable    see    answer    proprietary    weakened    interferon    sti    survival    ligands    restore    2m    restores    rates    worldwide    stimulator    pharmaceutical    activate    intent    marketing    regulatory    public    plan    option    business    sting    checkpoint    distant    stimunity    named    cancer    create    confirm    kill    cancers    anti    tumor    weaker    unresponsive    virus    chemical    licensing    natural    cells    first    immuno    tumours    develops    001    feasibility    patients    physicians    manufacturing    larger    date    validate    shown    beginning    companies    competitors    safe    drugs    fires    pipeline    million    particle    metastatic    innate    nevertheless    ligand    strategy    showed    immune    potent    fto    inhibitors    disruptive    vlps    demonstrated    private    inducing    tumour    encapsulates    immunotherapy    50    smei1    genes    edge    raised    therapeutic    biological    vlp    stimulatory    leader    cutting    update    company    letters    unseen   

Project "STI-001" data sheet

The following table provides information about the project.

Coordinator		 STIMUNITY SAS 

Organization address
address: RUE D'AMSTERDAM 57
city: PARIS
postcode: 75008
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STIMUNITY SAS FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Stimunity is a company that develops disruptive immuno-stimulatory biological drugs to restore the immune system against tumor cells. Immune checkpoint inhibitors showed great potential in cancer immunotherapy after achieving 5-year survival rates for patients with advanced or metastatic cancers, unseen by physicians before. This is a promising beginning. Nevertheless, 5 million patients worldwide remain unresponsive to immunotherapy and do not have any other therapeutic option. On average it represents 50% of all cancers. A promising answer to this problem is the development of new drugs that activate the STING (STimulator of INterferon Genes) pathway, which fires up the innate immune system of these unresponsive patients, inducing a potent and durable anti-tumour immune response. It is expected to be effective on a much larger number of cancer patients. Stimunity’s first product, named STI-001, restores weakened immune systems to kill tumour cells. It is especially effective on distant tumours. Competitors using chemical STING ligands have shown a much weaker immune response than STI-001. STI-001 is based on a safe cutting-edge Virus-Like Particle (VLP) technology that encapsulates the best-known natural STING ligand and efficiently deliver it into immune cells. There is high interest in STI-001, as demonstrated by public and private funding (raised €2.2M to date) and advanced discussions with major pharmaceutical companies (see Letters of Intent). SMEi1 project will allow Stimunity to i) confirm the technical feasibility of manufacturing STI-001, (ii) update the FTO, (iii) assess regulatory issues, (iv) validate the marketing and business plan. Our long-term goal is to develop a pipeline of products based on proprietary VLPs in cancer immunotherapy and create a long term out-licensing strategy as a worldwide leader in VLP-based immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STI-001" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STI-001" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More